Literature DB >> 375113

Kallikrein, kininogen and kinins in control of blood pressure.

I H Mills.   

Abstract

Plasma kallikrein releases bradykinin when activated by gram-negative septicemia or irreversible hemorrhagic shock. Pancreatitis releases glandular kallikrein causing hypotension and increased vascular permeability. Bradykinin in the brain produces hypertension. Renal kallikrein is released by high arterial pressure, vasodilators, low doses of noradrenaline, angiotensin II, mineralocorticoids and rapid volume expansion. It has a biphasic relation to sodium excretion. In essential hypertension, kallikrein release into the blood and urine is low and facilitates hypertension. High renin in Bartter's syndrome is balanced by high PGE and kallikrein without hypertension.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 375113     DOI: 10.1159/000181611

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  5 in total

1.  The plasma kallikrein kinin system in severely ill and traumatised patients.

Authors:  A D Cumming; C E Robertson; S S Jeffrey; J S Robson; I M Ledingham
Journal:  Arch Emerg Med       Date:  1984-09

2.  Kinin-forming system in the genesis of hypertension.

Authors:  J N Sharma
Journal:  Agents Actions       Date:  1984-02

3.  Receptors for bradykinin in intact cultured human fibroblasts. Identification and characterization by direct binding study.

Authors:  A A Roscher; V C Manganiello; C L Jelsema; J Moss
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

Review 4.  [Renal kallikrein-kinin system and control of blood pressure (author's transl)].

Authors:  A Distler; H P Wolff
Journal:  Klin Wochenschr       Date:  1979-10-01

5.  Urinary kallikrein in the rat: stimulation with angiotensin infusion but depression with increasing sodium concentration.

Authors:  I H Mills; G Lee; A A Brownlee
Journal:  J Physiol       Date:  1994-12-01       Impact factor: 5.182

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.